

# Iver Nordentoft

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9506191/publications.pdf>

Version: 2024-02-01

34  
papers

4,450  
citations

218677

26  
h-index

434195

31  
g-index

36  
all docs

36  
docs citations

36  
times ranked

7364  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1124.	7.1	538
2	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>Cancer Cell</i> , 2016, 30, 27-42.	16.8	486
3	Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. <i>Gut</i> , 2016, 65, 625-634.	12.1	381
4	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1547-1557.	1.6	298
5	Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue. <i>PLoS ONE</i> , 2014, 9, e98187.	2.5	284
6	Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties. <i>Cancer Research</i> , 2014, 74, 5758-5771.	0.9	237
7	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5437-5445.	7.0	232
8	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	27.8	221
9	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. <i>European Urology</i> , 2016, 70, 75-82.	1.9	174
10	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	12.8	159
11	Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. <i>European Urology</i> , 2017, 71, 961-969.	1.9	154
12	Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer. <i>Cell Reports</i> , 2014, 7, 1649-1663.	6.4	128
13	Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. <i>Nature Communications</i> , 2020, 11, 4858.	12.8	124
14	Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 395.	3.3	117
15	Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. <i>European Urology</i> , 2018, 73, 535-540.	1.9	112
16	Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 11702.	3.3	110
17	Widespread DNA hypomethylation and differential gene expression in Turner syndrome. <i>Scientific Reports</i> , 2016, 6, 34220.	3.3	106
18	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. <i>Cancer Research</i> , 2016, 76, 5894-5906.	0.9	87

#	ARTICLE	IF	CITATIONS
19	miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Medical Genomics, 2012, 5, 40.	1.5	86
20	Altered gene expression and repressed markers of autophagy in skeletal muscle of insulin resistant patients with type 2 diabetes. Scientific Reports, 2017, 7, 43775.	3.3	57
21	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
22	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Scientific Reports, 2018, 8, 1917.	3.3	50
23	Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patient-derived spheroid cultures. Molecular Oncology, 2018, 12, 132-147.	4.6	49
24	Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases. Modern Pathology, 2018, 31, 1869-1881.	5.5	47
25	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Molecular Oncology, 2016, 10, 1450-1460.	4.6	44
26	Increased expression of transcription factor TFAP2 $\pm$ correlates with chemosensitivity in advanced bladder cancer. BMC Cancer, 2011, 11, 135.	2.6	35
27	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Oncotarget, 2017, 8, 5774-5788.	1.8	22
28	Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases. International Journal of Cancer, 2022, 150, 1537-1548.	5.1	22
29	Epigenetic and transcriptomic consequences of excess X-chromosome material in 47,XXX females: A comparison with Turner syndrome and 46,XX females. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 279-293.	1.6	21
30	Mutational Analysis of Field Cancerization in Bladder Cancer. Bladder Cancer, 2020, 6, 253-264.	0.4	12
31	Abstract 913: Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. , 2019, , .		3
32	SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer. European Urology Open Science, 2021, 34, 59-67.	0.4	1
33	Genome-wide circulating tumor DNA monitoring for bladder cancer treatment management and organ preservation.. Journal of Clinical Oncology, 2021, 39, e16527-e16527.	1.6	0
34	Expression Analysis of cPLA2 Alpha Interacting TIP60 in Diabetic KKAY and Non-Diabetic C57BL Wild-Type Mice: No Impact of Transient and Stable TIP60 Overexpression on Glucose-Stimulated Insulin Secretion in Pancreatic Beta-Cells. Review of Diabetic Studies, 2007, 4, 147-158.	1.3	0